Q4 May Signal If Winlevi Can Give Wings To Sun’s US Specialty Sales
Sun-Cassiopea’s first-in-class topical androgen receptor inhibitor, Winlevi, appears off to an encouraging start in the US, generating prescriptions from 80% of targeted physicians. Can it hold out in the competitive acne therapy segment and add sheen to Sun’s specialty portfolio?
You may also be interested in...
Sun Forwards Specialty Strategy With $576m Concert Acquisition
Sun has struck a $576m deal to acquire Concert Pharmaceuticals, picking up lead product candidate deuruxolitinib as part of an acquisition that advances the Indian firm’s specialty pivot.
FDA Import Alert At Sun’s Site: Here’s The Long And Short Of The Impact
US FDA import alert at Halol site comes as a setback for Sun Pharma, but analysts shrug off wider concerns for now given the low dependence on the facility for future growth. Investors are, however, also tracking the escalated compliance situation for the firm’s Mohali plant, inherited via the Ranbaxy deal.
India’s Top Deck Backs Patent Box Policies, Four-Prong Strategy
C-suite executives from Sun Pharma, Zydus, Dr Reddy’s, Biocon, Piramal and Bharat Serums discuss future growth drivers as the generics opportunity shrinks. Favorable patent box policies, open-source innovation and areas like gene therapy and orphan diseases feature among ideas thrown up.